Roche, which put billions on the line a year ago across several ADC pacts, has returned to Innovent Biologics—this time delving into the China-based biopharma’s pipeline for IBI3009 ...

Swiss pharma giant Roche Holding AG RHHBY posted better-than-expected 2024 results and provided an encouraging outlook for ...

To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Roche has a big problem. With competition threatening some of its older and most lucrative biologic drugs, ...

有限公司、Fortvita Biologics (Singapore) Pte. Ltd.及福佑泰生物制药有限公司（连同公司统称为集团））（为一方）与F. Hoffmann-La Roche Ltd及Hoffmann-La Roche Inc ...

Innovent Biologics (HK:1801 ... Innovent Biologics has entered into an exclusive global license agreement with Roche for the development and commercialization of its novel DLL3-targeted antibody ...

all in one place with Analyst Top Stocks Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter Innovent Biologics has entered into an exclusive global license ...

Innovent Biologics, a biopharmaceutical company based in Shuzou, China, has agreed a collaboration with Roche to develop ...

Chinese biotech Innovent Biologics (OTCPK:IVBIY) (OTCPK:IVBXF) has entered into a collaboration and licensing agreement with Roche (OTCQX:RHHBY) to develop its experimental lung cancer therapy ...

In separate DLL3 antibody-drug conjugate (ADC) deals, Roche licensed from Innovent Biologics and Ideaya reached for Hengrui. Experts weighed in on the potential implications and lessons from two ...

Innovent Biologics Inc. has entered into a collaboration and exclusive license agreement with F. Hoffmann-La Roche Ltd. to advance the development of IBI-3009, a novel DLL3-targeted antibody-drug ...

Innovent Biologics and Roche have entered a partnership and exclusive licence agreement to accelerate the development of a delta-like ligand 3 (DLL3)-targeted antibody-drug conjugate (ADC ...